Leerink Partnrs Brokers Decrease Earnings Estimates for IDYA

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) – Stock analysts at Leerink Partnrs dropped their FY2026 EPS estimates for shares of IDEAYA Biosciences in a note issued to investors on Tuesday, September 9th. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings per share of ($4.05) for the year, down from their prior estimate of ($3.88). The consensus estimate for IDEAYA Biosciences’ current full-year earnings is ($3.07) per share. Leerink Partnrs also issued estimates for IDEAYA Biosciences’ FY2027 earnings at ($4.04) EPS.

A number of other research firms have also recently weighed in on IDYA. The Goldman Sachs Group raised shares of IDEAYA Biosciences to a “hold” rating and set a $25.00 target price on the stock in a research note on Thursday, July 10th. JPMorgan Chase & Co. increased their price target on shares of IDEAYA Biosciences from $72.00 to $74.00 and gave the company an “overweight” rating in a research note on Wednesday, September 3rd. Cantor Fitzgerald restated an “overweight” rating on shares of IDEAYA Biosciences in a report on Tuesday. Citigroup restated a “buy” rating on shares of IDEAYA Biosciences in a report on Tuesday. Finally, Wells Fargo & Company began coverage on shares of IDEAYA Biosciences in a report on Thursday, June 26th. They issued an “overweight” rating and a $44.00 target price on the stock. Twelve investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $42.75.

IDEAYA Biosciences Trading Up 0.9%

Shares of NASDAQ:IDYA opened at $24.93 on Thursday. IDEAYA Biosciences has a 1-year low of $13.45 and a 1-year high of $37.80. The firm has a market capitalization of $2.18 billion, a PE ratio of -6.58 and a beta of 0.12. The business’s 50 day moving average is $23.89 and its 200-day moving average is $20.72.

IDEAYA Biosciences (NASDAQ:IDYA) last released its earnings results on Tuesday, August 5th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.03). The business had revenue of $6.00 million for the quarter, compared to analysts’ expectations of $3.48 million. During the same period last year, the company posted ($0.68) earnings per share. IDEAYA Biosciences’s revenue was up NaN% on a year-over-year basis.

Hedge Funds Weigh In On IDEAYA Biosciences

Several hedge funds and other institutional investors have recently made changes to their positions in IDYA. Vanguard Group Inc. increased its position in IDEAYA Biosciences by 0.3% during the 1st quarter. Vanguard Group Inc. now owns 5,092,619 shares of the company’s stock worth $83,417,000 after purchasing an additional 14,535 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of IDEAYA Biosciences by 1.6% in the 2nd quarter. Geode Capital Management LLC now owns 2,113,164 shares of the company’s stock valued at $44,424,000 after purchasing an additional 33,286 shares during the last quarter. Fiera Capital Corp boosted its stake in shares of IDEAYA Biosciences by 26.6% in the 2nd quarter. Fiera Capital Corp now owns 1,532,269 shares of the company’s stock valued at $32,208,000 after purchasing an additional 322,404 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its stake in IDEAYA Biosciences by 4.2% during the second quarter. Adage Capital Partners GP L.L.C. now owns 1,238,094 shares of the company’s stock worth $26,025,000 after acquiring an additional 50,000 shares in the last quarter. Finally, Bank of America Corp DE boosted its stake in IDEAYA Biosciences by 5.9% during the fourth quarter. Bank of America Corp DE now owns 747,934 shares of the company’s stock worth $19,222,000 after acquiring an additional 41,390 shares in the last quarter. 98.29% of the stock is currently owned by institutional investors and hedge funds.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.